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Aim: The aim of this study is to compare the safety and durability of Sirolimus-eluting stent (SES) and bare metal stent (BMS) on the outcome of 
patients with chronic total occlusions (CTO). 
Methods: A prospective analysis of 226 patients (male 70.3%, mean age 69.9 yrs) with CTO (SES 106 cases 122 lesion and BMS 120 cases 136 
lesions) in six high volume Asian centers after successful stenting in CTOs was performed. Lesion locations of CTO were LAD 49.2%, LCX 21.7%, RCA 
24.8% and others 4.3%. Complete clinical follow-up to 3 years is being analyzed for 226 patients. 
Results: The baseline clinical characteristics between 2 groups were similar. Angiographic and clinical success were achieved in 100% of SES and 
99.2% of BMS with 0.4% stent thrombosis. At 3 years overall cardiac events of SES (7.5%) were much lower than BMS (33.8%) (p<0.001). See figure 
for clinical results.
Conclusion: The use of SES in patients with CTO was safe and feasible with low acute complication and low incidence of restenosis. These benefits 
are durable at least 4 years.
